With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS
The balancing act: How can we best protect patients from thromboembolic complications after major orthopaedic surgery without increasing the risk of bleeding? Drs Caprini, Maloney, and Barnes discuss management strategies and unmet needs in treatment options.
Where do the new and emerging oral anticoagulants target the coagulation cascade and how will they impact thromboprophylaxis in a variety of clinical settings. Join Drs Turpie and Weitz as they discuss the limitations of existing therapies and new developments in finding a replacement.
The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS
The balancing act: How can we best protect patients from thromboembolic complications after major orthopaedic surgery without increasing the risk of bleeding? Drs Caprini, Maloney, and Barnes discuss management strategies and unmet needs in treatment options.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
NATF's vision is to improve patient care, outcomes, and public health by utilizing a multidisciplinary approach to advance thrombosis research and education. NATF's legacy will be the improvement of patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy. NATF also seeks to broaden training opportunities for physicians, scientists, and other health professionals.